Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis
Status:
Recruiting
Trial end date:
2023-12-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether Orencia® (Abatacept) improves outcomes in
liver transplant patients with recurrent or de novo AIH (autoimmune hepatitis) that has not
responded to previous therapy. AIH that does not respond to steroids or conventional
immunotherapy often affects young patients and leads to irreversible liver damage. There is
currently no effective therapy for this condition.